233 related articles for article (PubMed ID: 34992253)
21. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.
Hou HA; Huang TC; Lin LI; Liu CY; Chen CY; Chou WC; Tang JL; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Blood; 2010 Jun; 115(25):5222-31. PubMed ID: 20368469
[TBL] [Abstract][Full Text] [Related]
22. WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience.
Valkova V; Vydra J; Markova M; Cerovska E; Vrana M; Marinov I; Cechova H; Cetkovsky P; Vitek A; Salek C
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e145-e151. PubMed ID: 33160932
[TBL] [Abstract][Full Text] [Related]
23. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
24. Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse.
Mashima K; Oh I; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Fujiwara SI; Hatano K; Sato K; Omine K; Muroi K; Kanda Y
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e521-e527. PubMed ID: 30181104
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
[No Abstract] [Full Text] [Related]
26. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
[TBL] [Abstract][Full Text] [Related]
27. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.
Jain P; Kantarjian H; Patel K; Faderl S; Garcia-Manero G; Benjamini O; Borthakur G; Pemmaraju N; Kadia T; Daver N; Nazha A; Luthra R; Pierce S; Cortes J; Ravandi F
Leuk Lymphoma; 2014 Jun; 55(6):1337-44. PubMed ID: 24004182
[TBL] [Abstract][Full Text] [Related]
28. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G
J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501
[TBL] [Abstract][Full Text] [Related]
30. Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.
Falini B; Dillon R
Blood Cancer Discov; 2024 Jan; 5(1):8-20. PubMed ID: 37917833
[TBL] [Abstract][Full Text] [Related]
31. A fast and simple approach for the simultaneous detection of hematopoietic chimerism, NPM1, and FLT3-ITD mutations after allogeneic stem cell transplantation.
Waterhouse M; Bertz H; Finke J
Ann Hematol; 2014 Feb; 93(2):293-8. PubMed ID: 23907410
[TBL] [Abstract][Full Text] [Related]
32. WT1 and TP53 as valuable diagnostic biomarkers for relapse after hematopoietic stem cell transplantation in acute myeloid leukemia.
Asghari-Ghomi A; Fallahian F; Garavand J; Mohammadi MH
Mol Biol Rep; 2024 Feb; 51(1):244. PubMed ID: 38300383
[TBL] [Abstract][Full Text] [Related]
33. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Minimal Residual Disease in Standard-Risk AML.
Ivey A; Hills RK; Simpson MA; Jovanovic JV; Gilkes A; Grech A; Patel Y; Bhudia N; Farah H; Mason J; Wall K; Akiki S; Griffiths M; Solomon E; McCaughan F; Linch DC; Gale RE; Vyas P; Freeman SD; Russell N; Burnett AK; Grimwade D;
N Engl J Med; 2016 Feb; 374(5):422-33. PubMed ID: 26789727
[TBL] [Abstract][Full Text] [Related]
35. Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.
Luskin MR; Carroll M; Lieberman D; Morrissette JJD; Zhao J; Crisalli L; Roth DB; Luger SM; Porter DL; Reshef R
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1961-1967. PubMed ID: 27478011
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
[TBL] [Abstract][Full Text] [Related]
37. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
[TBL] [Abstract][Full Text] [Related]
38. Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.
Kövy P; Őrfi Z; Bors A; Kozma A; Gopcsa L; Dolgos J; Lovas N; Harasztdombi J; Lakatos V; Király Á; Mikala G; Vályi-Nagy I; Reményi P; Andrikovics H
PLoS One; 2021; 16(6):e0253386. PubMed ID: 34153064
[TBL] [Abstract][Full Text] [Related]
39. [NPM1 High Mutant Allele Burden is an Adverse Prognostic Factor for AML Patients with Mutated NPM1].
Hou JX; Wang SJ; Liu YF; Hao QQ; Wang C; Li T; Bai JJ; Liao LX; Guo CY; Chang YY; Wang M; Sun H; Xie XS; Jiang ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):365-372. PubMed ID: 30998139
[TBL] [Abstract][Full Text] [Related]
40. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
Kayser S; Benner A; Thiede C; Martens U; Huber J; Stadtherr P; Janssen JW; Röllig C; Uppenkamp MJ; Bochtler T; Hegenbart U; Ehninger G; Ho AD; Dreger P; Krämer A
Blood Cancer J; 2016 Jul; 6(7):e449. PubMed ID: 27471865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
